Previous 10 | Next 10 |
Summary Novo Nordisk is a market leader and the only pure-play in the diabetes and obesity care space. The nature of the diabetes care business makes Novo Nordisk rather recession-proof. The stock priced in much of the assumed future growth and I have concerns about competition, esp...
Summary POINT Biopharma Global Inc. has a set of radioligand therapies in various stages. It has a major deal with Lantheus. The company has a long cash runway. POINT Biopharma Global Inc. ( PNT ) is a clinical-stage company developing radioligands targeting cancer. It...
Income investing can be a particularly effective investment strategy for those seeking to achieve financial independence. This is because, by buying high-quality businesses and sticking with the strategy for the long haul, your brokerage account can be flooded with passive income that can be used...
The Pharmaceutical Research and Manufacturers of America (PhRMA) announced Wednesday that Vas Narasimhan, Chief Executive of Novartis ( NYSE: NVS ) ( OTCPK:NVSEF ), assumed duties as the chair of the industry lobby’s director board. Narasimhan replaces Ramona Sequeira, pres...
Summary It's a challenging time for biotechs needing cash. Sana Biotechnology is such a company from the stable of Boston-based Flagship Pioneering. Sana was launched to pioneer a particular aspect of DNA-based therapies. This is new and revolutionary and likely to take time to matu...
Summary Erasca, Inc. is a clinical-stage biopharmaceutical developer of therapies for patients with RAS/MAPK pathway-driven cancers. Shares were dragged down sharply by headwinds from the Fed's hawkish stance and other macroeconomic issues. Erasca has some positive catalysts that co...
Novartis' ( NYSE: NVS ) unit Sandoz said on Monday that the U.S. Food and Drug Administration (FDA) accepted its biologics license application (BLA) for proposed biosimilar denosumab. The BLA includes all indications covered by the reference medicines, Amgen's ( NASDAQ: ...
The global contact lens market is experiencing rapid growth, with new technologies and innovations driving demand for the product. Contact lenses are becoming increasingly popular as corrective vision products, due to their convenience, comfort, and flexibility. In addition to this, contact lense...
Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...
The global contact lens market is experiencing rapid growth, with new technologies and innovations driving demand for the product. Contact lenses are becoming increasingly popular as corrective vision products, due to their convenience, comfort, and flexibility. In addition to this, contact lense...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...